EGFR and non-small cell lung carcinoma: One of the strengths of this study is that it was conducted between 2014–2020, where the treatment landscape for EGFR-mutated NSCLC had dramatically changed, spanning the approval of multiple first-, second-, and third-generation EGFR-TKIs, and allowing for selection of a relatively large cohort with a long follow-up to assess the prognostic impact TP53 co-mutations in this setting.